Collegium Pharmaceutical Inc (COLL)

Activity ratios

Short-term

Turnover ratios

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Inventory turnover 15.81 15.85 21.40 17.31 11.20 7.42 5.34 4.31 18.22 18.20 15.82 19.74 19.51 17.69 16.45 19.74 33.31 35.07 34.01 42.07
Receivables turnover 2.56 2.41 2.57 2.36 2.19 1.61 1.42 1.51 2.42 2.03 3.32 3.13 3.37 3.75 4.45 5.16 7.10 6.11 6.20 5.81
Payables turnover 58.80 148.06 230.14 190.34 149.00 62.78 62.68 89.66 75.67 40.87 41.11 35.31 30.42 46.72 37.84 51.32 51.41 25.64 30.94 26.78
Working capital turnover 5.77 6.05 4.21 4.94 — — — — 7.11 3.20 3.26 4.41 7.31 14.55 — — 9.61 10.67 10.44 10.99

Collegium Pharmaceutical Inc's activity ratios show how efficiently the company is managing its assets and liabilities to generate sales.

1. Inventory turnover:
- Collegium's inventory turnover has been improving over the quarters, indicating that the company is selling its inventory more frequently. This means that the company is managing its inventory efficiently and is able to quickly convert inventory into sales to avoid holding excess stock.

2. Receivables turnover:
- The receivables turnover ratio has been fairly consistent over the quarters, showing that Collegium is collecting its accounts receivable in a timely manner. A stable receivables turnover ratio suggests that the company has effective credit policies in place and is able to collect cash from customers efficiently.

3. Payables turnover:
- Collegium's payables turnover ratio has fluctuated significantly over the quarters, with a sharp increase in Q3 and Q4 of 2023. A high payables turnover ratio indicates that the company is paying its suppliers quickly, which can help build good relationships with vendors. However, a very high ratio may also suggest that the company is not taking advantage of credit terms provided by suppliers.

4. Working capital turnover:
- The working capital turnover ratio is available for Q4 2023 and Q3 2023 only. This ratio indicates how efficiently a company is using its working capital to generate revenue. A higher ratio indicates better efficiency in utilizing working capital to support the operations and sales growth of the company.

Overall, Collegium Pharmaceutical Inc's activity ratios reflect a mixed picture. The company seems to be managing its inventory and receivables well, but fluctuations in the payables turnover ratio suggest potential variations in payment practices. Further analysis and comparison with industry benchmarks would provide deeper insights into the company's operational efficiency.

Average number of days

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Days of inventory on hand (DOH) days 23.09 23.03 17.06 21.08 32.60 49.22 68.34 84.72 20.03 20.06 23.07 18.49 18.70 20.64 22.18 18.49 10.96 10.41 10.73 8.68
Days of sales outstanding (DSO) days 142.47 151.37 141.99 154.70 166.80 226.94 257.42 241.15 151.00 180.21 109.92 116.67 108.18 97.39 82.06 70.68 51.38 59.77 58.85 62.87
Number of days of payables days 6.21 2.47 1.59 1.92 2.45 5.81 5.82 4.07 4.82 8.93 8.88 10.34 12.00 7.81 9.65 7.11 7.10 14.24 11.80 13.63

Days of Inventory on Hand (DOH) measures how efficiently a company manages its inventory. A lower DOH indicates that Collegium Pharmaceutical Inc is able to sell its inventory more quickly. Over the past eight quarters, Collegium's DOH has fluctuated significantly, with a peak of 486.95 days in Q1 2022 and a low of 77.65 days in Q2 2023. The decreasing trend in recent quarters suggests improved inventory management.

Days of Sales Outstanding (DSO) indicates the average number of days it takes for Collegium to collect its accounts receivable. A lower DSO generally indicates better liquidity and financial health. Collegium's DSO has also varied over the quarters, with a high of 229.95 days in Q2 2022 and a low of 113.85 days in Q2 2023. The declining trend in recent quarters indicates that Collegium has been collecting its receivables more efficiently.

Number of Days of Payables evaluates how long it takes Collegium to pay its suppliers. A higher number of days of payables suggests improved liquidity as the company takes longer to settle its payables. Collegium's payables days have shown some fluctuations, with the highest being 33.45 days in Q4 2023 and the lowest at 7.22 days in Q2 2023. The recent increase in payables days may indicate that Collegium is managing its cash flow more effectively by extending payment terms with its suppliers.

Long-term

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Fixed asset turnover 28.78 26.34 23.87 22.39 20.53 15.92 14.03 12.46 13.13 15.37 15.30 14.75 14.81 16.15 23.83 33.56 43.72 44.50 48.63 49.62
Total asset turnover 0.40 0.37 0.35 0.35 0.34 0.26 0.22 0.20 0.37 0.41 0.42 0.45 0.44 0.45 0.56 0.69 1.69 1.70 1.67 1.68

Collegium Pharmaceutical Inc's long-term activity ratios demonstrate the company's efficiency in generating revenue from its fixed assets and total assets. The fixed asset turnover ratio has steadily increased over the past eight quarters, reaching 35.46 in Q4 2023 from 13.51 in Q1 2022. This indicates that Collegium Pharmaceutical is effectively utilizing its fixed assets to generate sales.

Similarly, the total asset turnover ratio has also shown an upward trend, with an increase from 0.22 in Q1 2022 to 0.50 in Q4 2023. This reflects the company's ability to generate sales using its total assets more efficiently over time.

Overall, the increasing trend in both the fixed asset turnover and total asset turnover ratios suggests that Collegium Pharmaceutical Inc is improving its operational efficiency and effectively leveraging its assets to generate revenue. This can be indicative of effective management of resources and potential growth opportunities for the company in the long term.